oral, ultralong-acting insulin analog

effective in Ph. IIa, hum. t1/2~3 d, 4% F dog

albumin-binding motif + reduced endocytosis

J. Med. Chem., Dec. 28, 2020

Novo Nordisk, Maaloev, DK

OI338

Novo oral insulin analog


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: